期刊
BLOOD
卷 121, 期 5, 页码 822-829出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-08-447367
关键词
-
类别
资金
- E-rare [2011-RARE-013-01]
- ANR (Investissements d'Avenir)
- Amgen SAS
- Chugai SA
- GIS Maladies Rares
- Institut de Veille Sanitaire
- Inserm
- Center de Reference des Deficits Immunitaires Hereditaires (CEREDIH: the French National Reference Center for Primary Immune Deficiencies
Congenital neutropenia is a group of genetic disorders that involve chronic neutropenia and susceptibility to infections. These neutropenias may be isolated or associated with immunologic defects or extra-hematopoietic manifestations. Complications may occur as infectious diseases, but also less frequently as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Recently, the transcription factor GATA2 has been identified as a new predisposing gene for familial AML/MDS. In the present study, we describe the initial identification by exome sequencing of a GATA2 R396Q mutation in a family with a history of chronic mild neutropenia evolving to AML and/or MDS. The subsequent analysis of the French Severe Chronic Neutropenia Registry allowed the identification of 6 additional pedigrees and 10 patients with 6 different and not previously reported GATA2 mutations (R204X, E224X, R330X, A372T, M388V, and a complete deletion of the GATA2 locus). The frequent evolution to MDS and AML in these patients reveals the importance of screening GATA2 in chronic neutropenia associated with monocytopenia because of the frequent hematopoietic transformation, variable clinical expression at onset, and the need for aggressive therapy in patients with poor clinical outcome. (Blood. 2013;121(5):822-829)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据